| | EVALUATION OF Senna (Cassia) alata (Linn) Roxb. LEAF TOPICAL SOLUTION VERSUS KETOCONAZOLE 2% AS TREATMENT FOR SCALP SEBORRHEIC DERMATITIS . . . |
Ongoing |
30 Nov -0001 |
| | Intravenous Tocilizumab in the Treatment of Patients with Severe and Critical COVID-19-related Pneumonia . . . |
Ongoing |
05 Oct 2020 |
| | Knowledge and Attitudes of Obstetric and Gynecologic Patients at Philippine General Hospital on Covid-19 Information and Prevention Guidelines of the Department of Health . . . |
Completed |
21 Feb 2022 |
| | The Effect in the Acid-base status, Electrolyte levels and Anion-gap following Initial Fluid Resuscitation in Children with Septic Shock with Normal saline, Lactated Ringers and Acetated Isotonic Elec . . . |
Ongoing |
30 Nov -0001 |
| |  A Study Evaluating the Safety and Immunogenicity of Mixing Different COVID-19 Vaccines and Vaccine Platforms in Filipino Adults. . . . |
Ongoing |
17 Feb 2022 |
| | INNOVATE- Inovio INO-4800 Vaccine Trial for Efficacy |
Terminated |
22 Jun 2022 |
| | A 12-Month Open-Label Study to Evaluate the Safety and Tolerability of Pregabalin as Adjunctive Therapy in Pediatric Subjects 1 Month to 16 Years of Age with Partial Onset Seizures and Pediatric and A . . . |
Completed |
17 Jul 2019 |
| | A 12-month, phase III, randomized, double-masked, multicenter, active-controlled study to evaluate the efficacy and safety of two individualized regimens of 0.5 mg ranibizumab vs. verteporfin PDT in p . . . |
Completed |
25 Jan 2022 |
| | A 12-week phase 3, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of once monthly subcutaneous erenumab 70 mg in adult chronic migraine patients . . . |
Ongoing |
25 Jun 2021 |
| | A 12-week randomized, participant-and investigator-blinded, placebo-controlled, parallel group study to explore the efficacy, pharmacodynamics, safety, and pharmacokinetics of two doses of inhaled CSJ . . . |
Pending |
30 Nov -0001 |
| | A 12-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled study to assess the efficacy and safety of CSJ117, when added to existing asthma therapy in patients ≥18 years of a . . . |
Ongoing |
21 May 2021 |
| | A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthm . . . |
Completed |
30 Mar 2021 |
| | A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis . . . |
Terminated |
12 Aug 2021 |
| | A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibitor . . . |
Completed |
25 Jan 2022 |
| | A 24-week multi-center, double-blind, placebo controlled dose-range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS) . . . |
Ongoing |
03 Feb 2022 |
| | A 24-week Treatment, Randomised, Parallel-group, Double blinded, Double- Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium bromide/Formoterol fumarate compared with Individual C . . . |
Completed |
11 Mar 2020 |
| | A 24-week, multicenter, randomized, double-blind, parallel-arm, placebo-controlled extension study to assess the safety of CSJ117, when added to existing standard of care asthma therapy in patients ≠. . . |
Pending |
30 Nov -0001 |
| | A 46-week, Double-blind, Placebo-controlled, Phase 3 Study with a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis . . . |
Terminated |
12 Aug 2021 |
| | A 5-year study to test BI 655130 in patients with Generalized Pustular Psoriasis who took part in previous studies with BI 655130 . . . |
Ongoing |
30 Jun 2022 |
| | A 52-week treatment, multi-center, randomized, doubleblind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with sa . . . |
Completed |
25 Jan 2022 |
| | A 52-week, multicenter, randomized, double-blind, double dummy, parallel-group, placebo-controlled study of fevipiprant once daily plus standard-of-care (SoC) for reduction of systemic corticostero . . . |
Terminated |
30 Mar 2021 |
| | A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma . . . |
Completed |
30 Mar 2021 |
| | A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis . . . |
Terminated |
05 Aug 2021 |
| | A 6-Month Safety, Efficacy, and Pharmacokinetic Trial of Delamanid in Pediatric Patients with Multi-Drug Resistant Tuberculosis . . . |
Completed |
09 Oct 2020 |
| | A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proli . . . |
Ongoing |
03 Feb 2022 |